Related Experiment Video

Updated: Jun 15, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Renin-angiotensin-aldosterone system gene polymorphisms in coronary artery bypass graft surgery patients

Georgia Ragia1, Eleftherios Nikolaidis, Anna Tavridou

  • 1Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|March 13, 2010
PubMed

Insights

Genetic variations in the renin-angiotensin-aldosterone system (RAAS) were not linked to severe coronary artery disease (CAD) in bypass surgery patients. However, a specific AGT gene variant was associated with hypertension in these individuals.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Medicine
  • Hypertension Research

Background:

  • Severe coronary artery disease (CAD) necessitates coronary artery bypass grafting (CABG).
  • Genetic polymorphisms within the renin-angiotensin-aldosterone system (RAAS) are implicated in CAD development.
  • Investigating specific RAAS gene variants in severe CAD patients is crucial.

Purpose of the Study:

  • To examine the association between angiotensin-converting enzyme (ACE), angiotensinogen (AGT), and angiotensin II type 1 receptor (AT(1) receptor) gene polymorphisms and severe CAD in CABG patients.
  • To assess the cumulative effect of these RAAS polymorphisms on severe CAD risk.
  • To explore potential links between RAAS gene variants and hypertension within the CABG patient cohort.

Main Methods:

  • Genotyping of 154 CABG patients and 155 non-CAD controls using PCR for AGT M235T, AGT T174M, AT(1) receptor A1166C, and ACE I/D polymorphisms.
  • Calculation of a RAAS gene score for each individual based on variant alleles.
  • Statistical analysis to compare polymorphism frequencies and RAAS gene scores between groups.

Main Results:

  • No significant association was found between the analyzed RAAS polymorphisms (AGT M235T, AGT T174M, ACE I/D, AT(1) receptor A1166C) and severe CAD in CABG patients.
  • The homozygous AGT 235TT genotype was more prevalent in hypertensive CABG patients compared to normotensive ones (21.7% vs. 6.3%, p=0.03).
  • The overall RAAS gene score did not differ between CABG patients and the control group.

Conclusions:

  • The studied RAAS gene polymorphisms are not associated with severe CAD in patients undergoing CABG.
  • A specific AGT 235TT genotype is associated with hypertension within the CABG patient population.
  • Further research may elucidate the role of specific RAAS gene variants in cardiovascular disease comorbidities.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...